---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Indication"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Indication. Topics: Population of the pivotal NATiV3 trial: adults with biopsy-proven noncirrhotic MASH and F2 to F3 fibrosis, Company wording of the target population: MASH with moderate and advanced fibrosis, Indication named in the FDA designations: treatment of MASH, and Population expansion planned: MASH with compensated cirrhosis. 4 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/indication"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Indication

<a id="heading-2.1.2.5"></a>

## 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

### Population of the pivotal NATiV3 trial: adults with biopsy-proven noncirrhotic MASH and F2 to F3 fibrosis

> “NATiV3 enrolled 1,009 adults with biopsy-proven non-cirrhotic MASH and F2/F3 fibrosis, with an additional 410 patients enrolled in an exploratory cohort.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

> “Male or female, aged ≥18 years at the time of signing informed consent”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.5-2"></a>

### Company wording of the target population: MASH with moderate and advanced fibrosis

> “Lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial for the treatment of patients with MASH with moderate and advanced fibrosis”

Source: [Inventiva AASLD 2026 abstracts release (2026)](https://inventivapharma.com/wp-content/uploads/INVENTIVA-AALSD-Abstracts-PR-EN-10.6.2026-1.pdf)

> “We are developing lanifibranor for the treatment of patients with metabolic dysfunction-associated steatohepatitis, a progressive, chronic liver disease.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.5-3"></a>

### Indication named in the FDA designations: treatment of MASH

> “The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

<a id="topic-2.1.2.5-4"></a>

### Population expansion planned: MASH with compensated cirrhosis

> “potentially expanding the addressable patient population to include patients with MASH and compensated cirrhosis through an additional Phase 3 outcome trial, rather than the originally planned Part 2 of our NATiV3 Phase 3 clinical trial of lanifibranor in MASH.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.5-5"></a>

### Proposed labeling

No evidence found.

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
